pneumoniae, is recognised as being the major protein virulence factor of this intransigent respiratory pathogen, the most common bacterial cause of communityacquired pneumonia (CAP) and associated organ damage (1) (2) (3) (4) . Importantly, Ply has been identified as being a key mediator of both acute lung injury (ALI) (5) (6) (7) (8) and myocardial damage (9, 10) in murine models of severe pneumococcal disease. In one such model of ALI, exposure of isolated, perfused lungs to recombinant Ply resulted in the development of pulmonary hypertension and microvascular barrier dysfunction, both of which are key features of this condition in humans (6, 7) . The underlying mechanisms appeared to involve increased pulmonary production of the bioactive lipid, platelet-activating factor (PAF), which, in turn, was proposed to activate production of the more potent platelet activator viz. the prostanoid, thromboxane A 2 (TxA 2 ), with resultant vasoconstriction and platelet activation (7) .
Although the authors speculated that PAF may have originated from Ply-exposed endothelial cells (7) , infiltrating neutrophils represent an alternative source of the bioactive lipid. Unlike macrophages, neutrophils express high levels of the PAFgenerating enzyme, PAF acetylhydrolase (11) . However, to our knowledge a possible link between Ply, neutrophils, PAF and platelet activation has not been described.
In the context of acute cardiovascular events associated with invasive pneumococcal disease, Ply, via its pore-forming activity, has been reported to inflict injury on myocardium through the formation of cardiac microlesions (9, 10) .
However, the existence of alternative mechanisms of Ply-mediated cardiotoxicity, possibly related to the pro-inflammatory/pro-thrombotic activities of the toxin are largely unexplored (12) (13) (14) .
To probe the existence of such mechanisms in the pathogenesis of Plymediated ALI and myocardial injury, we have investigated the effects of recombinant Ply on the production of PAF and TxA 2 by isolated, human blood neutrophils in vitro.
In addition, we have also explored the effects of Ply on the formation of potentially, pro-thrombotic, heterotypic aggregates of neutrophils and platelets (15) (16) (17) (18) (19) , focusing on the involvement of PAF, TxA 2 and other potent platelet activators, as well as the adhesion molecule, P-selectin (CD62P), in this process.
MATERIALS AND METHODS
Permission to draw blood from healthy, adult human volunteers was granted by the Research Ethics Committee, Faculty of Health Sciences, University of Pretoria.
Pneumolysin
Recombinant Ply and the pneumolysoid, delta6Ply, attenuated in respect of pore-forming activity, were prepared as described previously (20, 21) . The possible influence of contaminating endotoxin was excluded in both Ply preparations using the Endosafe ® -PTS™ system (Charles River Laboratories, Wilmington, MA, USA) which is based on the Limulus amoebocyte lysate kinetic chromogenic method. Both active Ply and delta6Ply contained <1 endotoxin unit (EU)/μg of protein after purification (1 EU is the lower limit of detection).
Chemicals
PSB 0739, WEB 2086, S 18886 and SCH 79797 antagonists of the platelet purinergic receptor, P2Y12, the PAF receptor, the TxA 2 TP prostanoid receptor, and the protease-activated receptor 1 (PAR1, thrombin activated) respectively were purchased from TOCRIS Bioscience, Bristol, UK. The oral thrombin inhibitor, dabigatran, was provided to one of us (GAR) by Boehringer-Ingelheim Pharma GmbH, Germany. All of these were dissolved to stock solutions of 10 mM in dimethylsulphoxide (DMSO) and used at final concentrations of 10 μM (final DMSO concentrations of 0.1%) in the assays described below. Appropriate DMSO control systems were included in all of the assays in which these receptor antagonists were used.
Mouse anti-human C62P blocking antibody (P-selectin, non-fluorochromelabelled), was purchased from Biolegend, London, UK. Unless stated, all other chemicals and reagents were purchased from the Sigma Chemical Co., St. Louis, MO, USA.
Preparation of neutrophils
Neutrophils were prepared from heparinised venous blood (5 units preservative-free heparin.mL -1 ) as described previously (22) . Briefly, neutrophil/erythrocyte pellets obtained following centrifugation of whole blood on Histopaque-1077 (Sigma Diagnostics) were resuspended and sedimented in 3% gelatin to remove most of the erythrocytes. Residual erythrocytes were then removed by differential lysis (brief treatment with 0.83% ammonium chloride) and the resultant neutrophil populations of high purity and viability (>90% and >95% respectively) suspended to a concentration of 1x10 7 cells.mL -1 in Hanks' balanced salt solution (HBSS, indicator-free, pH7.4).
PAF and TxA 2
Neutrophils (2x10 6 ) suspended in HBSS were prewarmed for 10 min at 37°C
followed by addition of one of the following: i) HBSS (negative control); ii) 
Neutrophil:platelet (NP) aggregate formation
In order to minimise spontaneous activation of platelets, NP-enriched buffy coat suspensions, enumerated for both cell types by standard haematological procedures, were used for these studies in keeping with earlier reports which used whole blood (23) (24) (25) . These cell suspensions were prepared from the heparinised blood of healthy, adult humans by sedimentation at 37°C and diluted 1:50 in HBSS to give a final volume of 1 ml. Following 5 min of preincubation at 37°C, recombinant
Ply (10-80 ng.mL 
RESULTS

Production of PAF and TxA 2 by Ply-activated neutrophils
These results are shown in figures 2A and 2B for PAF and TxA 2 respectively.
As shown in figure 2A , exposure of neutrophils to Ply resulted in dose-related activation of generation of PAF which achieved statistical significance at concentrations ≥20ng.mL -1 of the toxin, while the non-physiological positive control, A23187, as expected was extremely potent, and delta6Ply ineffective. The corresponding data for TxA 2 production by neutrophils are shown in figure 2B , which demonstrate similar, albeit lesser, effects.
Neutrophil viability
These results are shown in Figure 3 . Exposure of neutrophils to the highest concentrations of Ply (40 and 80 ng.mL ) and the calcium ionophore A23187 (2 μM, positive control) on neutrophil viability. *p < 0.01-p<0.001.
Effect of Ply on the formation of NP heterotypic aggregates
The median neutrophil and platelet counts of the buffy coats used in these and subsequent experiments were 4.67 x 10
3
.µL -1 and 451 x 10 -3
.µL -1 respectively, and the results are shown in Figure 3 . Addition of Ply to mixed NP suspensions resulted in dose-related formation of NP aggregates which achieved statistical significance at concentrations of ≥20 ng.mL -1 of the toxin and was greater than that observed with ADP, while delta6Ply was ineffective (Figure 4) . 
Effects of SCH 79797 on spontaneous, ADP-and thrombin-activated NP aggregation
To probe the receptor-targeted veracity of SCH 79797 (10µM) in the context of NP aggregate formation, the effects of this agent on spontaneous, ADP-or thrombin-activated NP aggregation were investigated and these results are shown in Figure 7 .
Addition of SCH 79797 to the mixed neutrophil and platelet suspensions during preincubation resulted in statistically significant formation of thrombin-activated heterotypic aggregates, but had no effect on either spontaneous or ADP-activated formation of NP aggregates. These findings confirm the selectivity of SCH 79797 for PAR1 and the probable involvement of this receptor in Ply-mediated NP aggregate formation, possibly via thrombin activation. 
Effect of dabigatran on Ply-mediated NP aggregation
The thrombin inhibitor, dabigatran, was used to explore the possible involvement of thrombin in Ply-mediated activation of PAR1 and these results are shown in Figure 8 . Dabigatran was found to attenuate thrombin-, but not Plymediated formation of NP aggregates, apparently excluding the involvement of thrombin derived from either the plasma or cellular elements of the buffy coat preparations in Ply-activated NP aggregation.
Effect of SCH 79797 on the pore-forming activity of Ply
An erythrocyte haemolysis assay was used to exclude possible interference of SCH 79797 with the pore-forming activity of Ply. Erythrocytes are particularly vulnerable to the lytic action of Ply. Briefly, the toxin (20 ng.mL 
DISCUSSION
The results of the current study demonstrate that exposure of neutrophils to Ply, at concentrations representative of those measured in the cerebrospinal fluid of patients with pneumococcal meningitis (26), caused dose-related generation of production of PAF, reaching levels which were about 3-fold higher than those of the untreated control system at the highest concentrations tested (40 and 80 ng.mL -1 ).
The pneumolysoid, delta6Ply, was ineffective, while the calcium ionophore, A23187, included as a positive control system, was more potent than Ply. Similar, but less impressive trends were observed in the case of TxA 2 , possibly indicative of intense competition for arachidonic acid by the range of prostanoid/eicosanoid/PAFgenerating enzymes present in activated neutrophils. Although not shown, similar effects were observed with TxB 2 , excluding conversion of TxA 2 to TxB 2 as a possible cause of the lesser effect of Ply on production of TxA 2 by neutrophils relative to PAF.
Although exposure of neutrophils to the toxin at concentrations of 40 and 80 ng.mL -1 resulted in loss of viability, these effects were modest and unlikely to have contributed to the observed activation of production of PAF and TxA 2. In this context, it is noteworthy that some types of mammalian cell can withstand the cytotoxic actions of Ply due to the existence of a mechanism which promotes microvesicle shedding of toxin pores (27) . Ply-mediated pore formation in the plasma membrane of inflammatory cells does, however, result in an influx of extracellular Ca 2+ which either activates or sensitises the cells for increased pro-inflammatory activity (12) (13) (14) .
A possible association between the production of PAF and TxA 2 by Ply- The apparent involvement of triggering of PAR1 on platelets in NP heterotypic aggregation was an unexpected finding, which is most likely a secondary, albeit important, amplification mechanism resulting from interaction of the receptor with putative activators derived from Ply-activated platelets and/or neutrophils, reinforcing and sustaining NP adhesion. Possible contenders include prothrombin released from platelet α-granules (29) , which may be converted to thrombin by the action of pro-thrombinase expressed on neighbouring monocytes (30). Activation of PAR4 which is also expressed on platelets and activated by thrombin, albeit at a slower rate than PAR1, may also contribute to NP aggregation (31) . However, the lack of an effect of the thrombin inhibitor, dabigatran, on Ply-mediated NP aggregation appears to exclude any meaningful involvement of thrombin activation of PARs. An alternative, albeit unexplored mechanism, implicates the serine proteinases, elastase and proteinase 3, as well as the matrix metalloproteinases 8 and 9 expressed by Plyexposed adherent neutrophils (13, 32) all of which are known activators of PAR 1 (33, 34) , while cathepsin G has been reported to activate PAR 4 (35) . Addressing this issue is, however, beyond the scope of the current study given the spectrum of neutrophil-derived proteinases and their probable interactions, compounded by the requisite large number of enzyme inhibitors.
Together with the observation that inclusion of an anti-CD62P monoclonal antibody caused almost complete attenuation of Ply-mediated NP aggregate formation, the aforementioned observations appear to be consistent with a sequence of events whereby exposure of platelets to Ply results in influx of extracellular Ca 2+ , as described previously (14) , Ca 2+ -dependent mobilisation of α-granules, upregulated surface expression of CD62P, and adhesion of neighbouring neutrophils. In this context, interactions between CD62P expressed on platelets and its counter ligand, P-selectin glycoprotein ligand-1 (PSGL-1) expressed on platelets and other cell types, are considered to be the primary mediators of platelet homotypic and heterotypic aggregation (15, 17, 24, 36) . Although platelet-derived CD40 ligand has also been reported to mediate this type of interaction, the results of the current study appear to implicate CD62P as being the major player in the proadhesive actions of Ply (37, 38) . Although speculative, initial CD62P-dependent NP adhesion is then reinforced by neutrophil proteinase-mediated activation of platelet PAR1, resulting in the formation of more stable NP aggregates. Given that endothelial cells also express PAR1 (39) , it is likely, albeit unexplored that exposure of endothelium to Ply also results in Ca 2+ influx and upregulation of endothelial CD62P. This, in turn, may promote the binding of neutrophils and NP aggregates favouring activation of endothelial PAR1 and endothelial dysfunction (39) .
In agreement with the findings of the current study, CD62P-dependent formation of NP aggregates following exposure of whole blood to the bacterial poreforming toxins, streptolysin-O or Staphylococcus aureus α-hemolysin, has been described previously (23, 24) . In the case of the former, the authors proposed a link between streptolysin-O production, formation of NP aggregates, and vascular occlusions and tissue damage during infection with group A streptococci (23) . In the case of α-hemolysin, heterotypic aggregate formation was linked to alveolar capillary destruction in haemorrhagic/necrotising pneumonia caused by communityassociated, methicillin-resistant S. aureus (24) . However, unlike the current study, neither of these earlier studies, investigated the pathophysiological mechanisms underpinning toxin-mediated aggregate formation. Very recently, Zhang et al. in a study focused primarily on the S. suis pore-forming toxin, suilysin, reported that this toxin, as well as Ply, promoted NP aggregation in vitro by a Ca 2+ -and P-selectindependent mechanism as described in the current study (40) . However, in the study reported by Zhang et al. Ply was used at a concentration considerably higher (800 ng.mL -1 , fixed) than those used in the current study (10-80 ng.mL -1 ), while these authors did not investigate the involvement of platelet-activating receptors in either suilysin-or Ply-mediated NP aggregation (40) While the exact clinical significance of the findings of the current study await clarification, they do, however, imply a multifaceted role for Ply in the pathogenesis of lung, heart and other types of organ damage during severe pneumococcal disease. Notwithstanding direct Ply-mediated organ damage (6) (7) (8) (9) (10) , the effects of the toxin described here are also consistent with a pathogenic role for Ply-mediated formation of large, intravascular NP aggregates with resultant microvascular occlusion. Importantly, activated platelets and NP aggregates may also promote tissue injury by amplifying the inflammatory response. On a cautionary note, however, should these harmful activities of the toxin be evident in the clinical setting, therapeutic targeting may prove difficult given the drawbacks and side effect profile of a commercially available PAR1 antagonist, vorapaxar (41) , as well as the current lack of pharmacological agents which directly inhibit Ply. In this context, inhibitors of bacterial protein synthesis, especially macrolide antibiotics, may offer the best therapeutic option (42) .
